Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
2 hedge funds and large institutions have $2.57M invested in Blueprint Medicines in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.04% less ownership
Funds ownership: 0.04% → 0% (-0.04%)
0% less capital invested
Capital invested by funds: $2.58M → $2.57M (-$2.49K)
60% less funds holding
Funds holding: 5 → 2 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VanEck Associates
New York
|
-$17K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$8.54K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.95K |
BPMC Hedge Fund Activity: Q4 2025 in Review
2 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2025, worth a combined $2.57M — down 0.1% from $2.58M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BPMC and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was VanEck Associates, exiting entirely with an estimated $17K sold.
- 2 institutional investors held Blueprint Medicines (BPMC) as of Q4 2025, down from 5 in Q3 2025.
- Funds reported $2.57M of Blueprint Medicines stock for Q4 2025, down 0.1% quarter-over-quarter.
- 0 funds opened new Blueprint Medicines positions in Q4 2025 and 3 closed out, a net change of -3 holders.
- The largest Blueprint Medicines seller in Q4 2025 was VanEck Associates, an estimated $17K sold.
Based on aggregated 13F filings for Q4 2025.